Next Article in Journal
High Seroprevalence of Antibodies against Arboviruses among Pregnant Women in Rural Caribbean Colombia in the Context of the Zika Virus Epidemic
Next Article in Special Issue
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Previous Article in Journal
Natural Killer (NK) Cell Expression of CD2 as a Predictor of Serial Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
Previous Article in Special Issue
Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody
Review

IgE Antibodies against Cancer: Efficacy and Safety

1
St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, London SE1 9RT, UK
2
School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Hospital, London SE1 9RT, UK
3
Epsilogen Ltd., London BioScience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK
4
Guy’s Cancer Centre, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK
5
Breast Cancer Now Research Unit, School of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Hospital, London SE1 9RT, UK
*
Author to whom correspondence should be addressed.
Antibodies 2020, 9(4), 55; https://doi.org/10.3390/antib9040055
Received: 7 September 2020 / Revised: 25 September 2020 / Accepted: 9 October 2020 / Published: 16 October 2020
(This article belongs to the Special Issue Antibody Engineering for Cancer Immunotherapy)
Immunoglobulin E (IgE) antibodies are well known for their role in allergic diseases and for contributions to antiparasitic immune responses. Properties of this antibody class that mediate powerful effector functions may be redirected for the treatment of solid tumours. This has led to the rise of a new class of therapeutic antibodies to complement the armamentarium of approved tumour targeting antibodies, which to date are all IgG class. The perceived risk of type I hypersensitivity reactions following administration of IgE has necessitated particular consideration in the development of these therapeutic agents. Here, we bring together the properties of IgE antibodies pivotal to the hypothesis for superior antitumour activity compared to IgG, observations of in vitro and in vivo efficacy and mechanisms of action, and a focus on the safety considerations for this novel class of therapeutic agent. These include in vitro studies of potential hypersensitivity, selection of and observations from appropriate in vivo animal models and possible implications of the high degree of glycosylation of IgE. We also discuss the use of ex vivo predictive and monitoring clinical tools, as well as the risk mitigation steps employed in, and the preliminary outcomes from, the first-in-human clinical trial of a candidate anticancer IgE therapeutic. View Full-Text
Keywords: IgE; antibodies; cancer; immunotherapy; AllergoOncology; safety; type I hypersensitivity; anaphylaxis; in vivo models; basophil activation test (BAT) IgE; antibodies; cancer; immunotherapy; AllergoOncology; safety; type I hypersensitivity; anaphylaxis; in vivo models; basophil activation test (BAT)
Show Figures

Graphical abstract

MDPI and ACS Style

Chauhan, J.; McCraw, A.J.; Nakamura, M.; Osborn, G.; Sow, H.S.; Cox, V.F.; Stavraka, C.; Josephs, D.H.; Spicer, J.F.; Karagiannis, S.N.; Bax, H.J. IgE Antibodies against Cancer: Efficacy and Safety. Antibodies 2020, 9, 55. https://doi.org/10.3390/antib9040055

AMA Style

Chauhan J, McCraw AJ, Nakamura M, Osborn G, Sow HS, Cox VF, Stavraka C, Josephs DH, Spicer JF, Karagiannis SN, Bax HJ. IgE Antibodies against Cancer: Efficacy and Safety. Antibodies. 2020; 9(4):55. https://doi.org/10.3390/antib9040055

Chicago/Turabian Style

Chauhan, Jitesh; McCraw, Alex J.; Nakamura, Mano; Osborn, Gabriel; Sow, Heng S.; Cox, Vivienne F.; Stavraka, Chara; Josephs, Debra H.; Spicer, James F.; Karagiannis, Sophia N.; Bax, Heather J. 2020. "IgE Antibodies against Cancer: Efficacy and Safety" Antibodies 9, no. 4: 55. https://doi.org/10.3390/antib9040055

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop